– Participation of Mico, Signite Partners, BNH Investment, and Shinhan Capital
– Recognized for laser spectroscopy and artificial intelligence (AI) medical diagnosis total solution technology, from skin tissue to blood
Speclipse (CEO Byun Seong-hyun) announced on the 13th that it had recently attracted an investment worth 9 billion won.
As a result, Speclipse recorded a cumulative investment of 15.1 billion won. Speclips is a company specializing in medical diagnosis based on laser spectroscopy technology and artificial intelligence (AI) and has been a member of the Born2Global Center since this year.
Signite Partners, BNH Investment, and Shinhan Capital participated in the investment, and highly evaluated the innovation and marketability of Speclipse’s technology. Myco, which secured majority shareholder status early this year, also participated in this new stock investment and is fully supporting the growth of Speclipse along with its affiliate Myco Biomed.
Speclips, which started as a cancer diagnostic device developer, was founded in 2015 by graduates with master’s and doctoral degrees from Stanford University in the United States. The first product, Spectra-Scope, a skin cancer diagnostic device, obtained overseas medical device certification in Australia, Europe, and Brazil in 2020, and is building a sales network in over 20 countries around the world.
Spectra-Scope diagnoses suspected skin cancer areas in real time and non-invasively based on Laser Induced Plasma Spectroscopy (LIPS) technology and AI. It is evaluated as having high market demand as it can identify skin cancer with a 95% private rating and a specificity of 87%, thereby reducing unnecessary biopsies and increasing patient convenience.
Speclips is expanding the application target of its laser spectroscopy and AI technologies from tissue to blood. To overcome the limitations of existing blood analysis technology, various biomarkers in the blood are simultaneously detected with high sensitivity using laser spectroscopy technology. We are attempting early diagnosis of stomach cancer, Alzheimer’s, etc. by learning the large amount of blood spectroscopy data obtained through deep learning. With the current technology development stage, it is expected that it will be able to change the paradigm in the liquid biopsy field in the future.
Seonghyun Byun, CEO of Speclipse, said, “The skin cancer that Spectra-Scope targets is a cancer with a high prevalence in white people, and in the United States, an annual market worth 12 trillion won is formed just for skin cancer biopsy alone.” He added, “Doctors “We examine the lesion with a dermascope (magnifying glass) and then decide whether or not to conduct a biopsy. However, there are cases where the biopsy target is misjudged depending on the doctor’s skill level, etc., and we will be able to compensate for this with Speclipse’s technology,” he said. CEO Byun added, “By expanding Speclipse’s laser spectroscopy and AI-based diagnostic technology from skin tissue to blood, it will be a game changer in the liquid biopsy market for not only skin cancer but also various cancers that have been difficult to diagnose early in the past.” .
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news